CN119212690A - 包含meai和n-酰基乙醇胺的组合物及其用途 - Google Patents

包含meai和n-酰基乙醇胺的组合物及其用途 Download PDF

Info

Publication number
CN119212690A
CN119212690A CN202380038816.0A CN202380038816A CN119212690A CN 119212690 A CN119212690 A CN 119212690A CN 202380038816 A CN202380038816 A CN 202380038816A CN 119212690 A CN119212690 A CN 119212690A
Authority
CN
China
Prior art keywords
meai
pharmaceutical composition
certain embodiments
salt
consumption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380038816.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·祖洛夫-沙尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Climax Labs Inc
Original Assignee
Kelimai Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kelimai Pharmaceutical Co filed Critical Kelimai Pharmaceutical Co
Publication of CN119212690A publication Critical patent/CN119212690A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380038816.0A 2022-03-07 2023-03-06 包含meai和n-酰基乙醇胺的组合物及其用途 Pending CN119212690A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317257P 2022-03-07 2022-03-07
US63/317257 2022-03-07
PCT/IB2023/052091 WO2023170552A1 (en) 2022-03-07 2023-03-06 Compositions comprising meai and n-acylethanolamines and uses thereof

Publications (1)

Publication Number Publication Date
CN119212690A true CN119212690A (zh) 2024-12-27

Family

ID=85706794

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380038816.0A Pending CN119212690A (zh) 2022-03-07 2023-03-06 包含meai和n-酰基乙醇胺的组合物及其用途

Country Status (9)

Country Link
US (1) US20250302773A1 (https=)
EP (1) EP4489741A1 (https=)
JP (1) JP2025508052A (https=)
CN (1) CN119212690A (https=)
AU (1) AU2023231494A1 (https=)
CA (1) CA3244360A1 (https=)
IL (1) IL315486A (https=)
MX (1) MX2024010596A (https=)
WO (1) WO2023170552A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120225185A (zh) * 2022-09-21 2025-06-27 克力迈医药公司 5-甲氧基-2-氨基茚满(“meai”)在用于治疗代谢综合征的方法中的用途
WO2025196662A1 (en) * 2024-03-20 2025-09-25 Clearmind Labs Corp. Compositions and methods for treating eating disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
JP3342491B2 (ja) 1993-08-06 2002-11-11 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
WO2005002524A2 (en) * 2003-07-02 2005-01-13 The Regents Of The University Of California COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα
CN107406369B (zh) * 2014-12-09 2021-01-15 以西结·戈兰 放纵行为调节剂
ES2580508B1 (es) * 2016-04-11 2018-09-12 Servicio Andaluz De Salud Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.

Also Published As

Publication number Publication date
JP2025508052A (ja) 2025-03-21
EP4489741A1 (en) 2025-01-15
AU2023231494A1 (en) 2024-09-05
MX2024010596A (es) 2025-01-09
CA3244360A1 (en) 2023-09-14
US20250302773A1 (en) 2025-10-02
WO2023170552A1 (en) 2023-09-14
IL315486A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP7442095B2 (ja) ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法
RS64481B1 (sr) Lečenje alchajmerove bolesti kod posebne populacije pacijenata
CN119212690A (zh) 包含meai和n-酰基乙醇胺的组合物及其用途
CN121079078A (zh) 任选地与n-酰基乙醇胺组合地包含麦角酸二乙酰胺的组合物及其用途
EP4661867A1 (en) Compositions comprising n,n-dimethyltryptamine, optionally in combination with n-acylethanolamines and uses thereof
WO2024166058A1 (en) Compositions comprising psilocybin, optionally in combination with n-acylethanolamines and uses thereof
CN120225185A (zh) 5-甲氧基-2-氨基茚满(“meai”)在用于治疗代谢综合征的方法中的用途
US20250325500A1 (en) Use of 5-methoxy-2-aminoindan ("meai") in methods for treating cocaine addiction
CN120936351A (zh) 任选地与n-酰基乙醇胺组合地包含3,4-亚甲基二氧基甲基苯丙胺的组合物及其用途
CN120916770A (zh) 任选地与n-酰基乙醇胺组合地包含伊博格碱的组合物及其用途
TW202024040A (zh) 胺基甲酸酯化合物及包括該化合物之組合於預防、緩解或治療急性壓力症或創傷後壓力症之用途
CN120897738A (zh) 用于治疗抑郁症的包含5-甲氧基-2-氨基茚满的组合物
CN104906501A (zh) 治疗银屑病的中药组分组合物
ES2326355B1 (es) Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico.
CN120936348A (zh) 任选地与n-酰基乙醇胺组合地包含氯胺酮的组合物及其用途
CA3134885A1 (en) Compositions and methods for potentiating derivatives of 4-aminophenols
CN112843065A (zh) 一种用于认知障碍的药物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20260129

Address after: British Columbia

Applicant after: Climax Labs Inc.

Country or region after: Canada

Address before: Israel Tel Aviv

Applicant before: Kelimai Pharmaceutical Co.

Country or region before: Canada